Document is current
Any future updates will be listed below
-
Authors
Qiao, Yongfeng
Han, Yanjun
Zhao, Lu
Gao, Wenjing
Hu, Hong
Su, Chao
Zheng, Anqi
Sun, Junqing
Tian, Mingxiong
Wu, Yarong
Bai, Lianmei
Lei, Yuping
Wu, Jiahao
Zhang, Weibing
Han, Pu
Li, Xiaoyu
Dong, Chunbo
Wang, Haidong
Liu, Zhida
Han, Pengcheng
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (32222006)
- License Information
-
More Information
Article History
Received: 20 April 2025
Revised: 5 September 2025
Accepted: 9 September 2025
First Online: 15 October 2025
Declarations
:
: Animal studies were conducted following approval from the Research Ethics Committee of the Institute of Microbiology, Chinese Academy of Sciences (APIMCAS2022124) and Institutional Animal Care and Use Committee of Shanxi Agricultural University (SXAU-EAW-2023M.DF.001017216). The studies were conducted in accordance with the local legislation and institutional requirements.
: Not applicable.
: Competing interests Z.L., P.H., C.D., Y.Q., Y.H., H.H. and L.Z. have filed a patent for protecting a bifunctional therapeutic protein ACE2 (M)-Fc-GP130-TNFR2 for the treatment of patients with SARS-CoV-2 infection. Author Hong Hu is an employee in Ankerui (Shanxi) Biological Cell Co, but has no potential relevant financial or non-financial interests to disclose. The other authors have no conflicts of interest to declare.
